Julio García‐Suárez

Author

Julio García‐Suárez

Hospital Universitario Príncipe de Asturias ORCID

Also Known As

J Garcia Suárez, J Garcia-Suarez, J García Suárez, J. Garcia Suarez, J. Garcia-Suarez, J. Garcia‐Suarez, J. García Suárez, J. García-Suárez, J. García‐Suárez, J. Suarez

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Príncipe de Asturias Universidad de Alcalá Hospital Universitario Ramón y Cajal Hospital Universitario Puerta de Hierro Majadahonda Hospital Clínico San Carlos

About

Julio García‐Suárez is an author at Hospital Universitario Príncipe de Asturias specializing in medicine, hematology, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	373
2	Health Sciences	1	1	34
3	Allergy	1	1	25
4	Biology	1	1	10
5	Cell Biology	1	1	11

Julio García‐Suárez

Publications

Citations

H-Index

Page 1

	Year	Citations
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study Julio García‐Suárez, Javier de la Cruz, Ángel Cedillo, Journal of Hematology & Oncology	2020	238
Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: Impact of novel therapies Julio García‐Suárez, Dunia de Miguel, Isabel Krsnik, American Journal of Hematology ImmunodeficienciesImmunologyPathologyImmunotherapyHuman Retrovirus	2005	118
HCV‐associated thrombocytopenia: clinical characteristics and platelet response after recombinant α2b‐interferon therapy Julio García‐Suárez, Carmen Burgaleta, Nuria Hernanz, British Journal of Haematology Hepatitis C VirusImmunologyPathologyRecombinant α2B‐interferon TherapyThrombosis	2000	102
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study Isabel Regalado‐Artamendi, Ana Jiménez Ubieto, José‐Ángel Hernández‐Rivas, HemaSphere	2021	71
Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3- natural killer cells subset [see comments] Julio García‐Suárez, Alfredo Prieto, Eduardo Reyes, Blood	1993	53
Dose‐adjusted EPOCH plus rituximab is an effective regimen in patients with poor‐prognostic untreated diffuse large B‐cell lymphoma: results from a prospective observational study Julio García‐Suárez, Helena Bañas, Ignacio Arribas, British Journal of Haematology	2006	44
Apoptotic rate: A new indicator for the quantification of the incidence of apoptosis in cell cultures Alfredo Prieto, David Díaz, Hugo Barcenilla, Cytometry	2002	38
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia María‐Belén Vídriales, Estefanía Pérez‐López, Carlota Pegenaute, Leukemia Research Hematological MalignancyFlow CytometryComplementary ToolMedicineMixed-phenotype Acute Leukemia	2015	34
Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals. Alfredo Prieto, Julio García‐Suárez, Eduardo Reyes, PubMed	1993	32
A team-based multidisciplinary approach to managing peripherally inserted central catheter complications in high-risk haematological patients: a prospective study Natalia Curto‐García, Julio García‐Suárez, Marta Callejas Chavarria, Supportive Care in Cancer Team-based Multidisciplinary ApproachPrimary CareCentral Catheter ComplicationsHigh-risk Haematological PatientsEmergency Surgery	2015	29

Page 1